Novo Nordisk A/S vs Orsted A/S
A head-to-head of Novo Nordisk A/S (NVO) and Orsted A/S (DOGEF) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | NVO | DOGEF |
|---|---|---|
| Market Cap | $182.56B | $537.44B |
| P/E (TTM) | 2.19 | 126.35 |
| Forward P/E | 12.24 | 0.66 |
| P/S | 0.59 | 7.34 |
| P/B | 1.15 | 2.00 |
| EV/EBITDA | 8.12 | 15.58 |
| Dividend Yield | 23.40% | — |
| Profit Margin | 33.14% | 2.97% |
| Gross Margin | 80.98% | -2.70% |
| Operating Margin | 41.30% | -2.70% |
| Revenue Growth (YoY) | -7.63% | +12.75% |
| FCF Yield | 15.88% | -5.87% |
| Debt / Equity | 67.49 | 83.48 |
| Current Ratio | 0.80 | 1.94 |
Which is better: Novo Nordisk A/S or Orsted A/S?
- ✓Larger by market cap: Orsted A/S
- ✓Cheaper valuation (lower P/E): Novo Nordisk A/S
- ✓More profitable (net margin): Novo Nordisk A/S
- ✓Faster revenue growth: Orsted A/S
- ✓Higher free-cash-flow yield: Novo Nordisk A/S
Across 12 available metrics, Novo Nordisk A/S leads 9–3.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Novo Nordisk A/S with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.